GlyHealth Biomarkers
Inflammatory Bowel Disease (IBD)
Key Facts
About Avenna
Avenna, spun out from Ludger in 2017, is a private, pre-revenue diagnostics company leveraging glycomics to develop blood-based biomarkers for chronic inflammatory diseases. Its core platform, GlyHealth, aims to measure and track chronic inflammation without acute inflammation interference, facilitating early detection and treatment personalization. The company targets individuals, clinicians, and biopharma partners with the goal of reducing healthcare costs and improving patient outcomes in a vast market driven by non-communicable diseases.
View full company profileAbout Avenna
Avenna, spun out from Ludger in 2017, is a private, pre-revenue diagnostics company leveraging glycomics to develop blood-based biomarkers for chronic inflammatory diseases. Its core platform, GlyHealth, aims to measure and track chronic inflammation without acute inflammation interference, facilitating early detection and treatment personalization. The company targets individuals, clinicians, and biopharma partners with the goal of reducing healthcare costs and improving patient outcomes in a vast market driven by non-communicable diseases.
View full company profileAbout Avenna
Avenna, spun out from Ludger in 2017, is a private, pre-revenue diagnostics company leveraging glycomics to develop blood-based biomarkers for chronic inflammatory diseases. Its core platform, GlyHealth, aims to measure and track chronic inflammation without acute inflammation interference, facilitating early detection and treatment personalization. The company targets individuals, clinicians, and biopharma partners with the goal of reducing healthcare costs and improving patient outcomes in a vast market driven by non-communicable diseases.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease (IBD) Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM2001 | Harbour BioMed | Discovery |
| Metabolite Delivery Platform (Therapeutic Programs) | ClostraBio | Pre-clinical |
| ABO21009 | AboleIIs Pharma | Phase 1 |
| GTI-850 | GSNO Therapeutics | Pre-clinical |
| CK-0045 | Cytoki Pharma | Pre-clinical/Research |
| MV-010 | MV BioTherapeutics | Preclinical |
| NM81 | Numab Innovation | Pre-clinical |
| LIAISON® Calprotectin | DiaSorin | Commercial |
| SL-325 | Shattuck Labs | Phase 2 |
| SL-425 | Shattuck Labs | Phase 1 |
| VE202 | PureTech Health | Phase 2 |